Myocardial insulin resistance associated with chronic hypertriglyceridemia and increased FFA levels in Type 2 diabetic patients

We evaluated the influence of chronic hypertriglyceridemia and endothelial dysfunction on myocardial glucose uptake (MGU) in Type 2 diabetic patients without coronary heart disease. Patients were divided into two groups according to fasting triglyceride (TG) levels: 5.4 ± 1.1 and 1.5 ± 0.3 mmol/l for high- and normal-TG groups, respectively. Five subjects were assigned to the high-TG group and 11 to the normal-TG group. Age, gender, body mass index, systolic and diastolic blood pressure, glucose, insulin, HbA1c, cholesterol, and HDL cholesterol were similar in the two groups, whereas free fatty acid (FFA) levels were higher in the high-TG group basally and at the end of the clamp. Furthermore, five healthy subjects were subjected to the same protocol and used as the control group. MGU was assessed by using 18F-labeled 2-fluoro-2-deoxy-d-glucose under hyperglycemic-hyperinsulinemic conditions. Basal endothelin-1 and nitric oxide levels were significantly higher in the high-TG group than in the normal-TG and control groups, and cGMP and maximal postischemic vasodilation were significantly decreased in the high-TG group compared with the normal-TG and control groups. However, significant alterations were found in the same parameters in the normal-TG group compared with the control group. By the end of the hyperglycemic clamp, in the high-TG group, MGU was ∼40 and 65% of that in the normal-TG and control groups. MGU negatively correlated with TG, FFA, and endothelin-1, whereas a positive correlation was found with cGMP and maximal postischemic vasodilation. In conclusion, increased TG and FFA levels are risks, in addition to Type 2 diabetes mellitus, for myocardial insulin resistance, endothelial dysfunction, and alteration of nitric oxide/cGMP levels.

Download Full-text

Investigating ADAMTS7 and ADAMTS12 levels in prediabetic and Type 2 diabetic patients

Biomarkers in Medicine ◽

10.2217/bmm-2020-0161 ◽

2021 ◽

Author(s):

Mercan Taştemur ◽

Selvihan Beysel ◽

Sema Hepşen ◽

Sanem Öztekin ◽

Erman Çakal ◽

...

Keyword(s):

Inflammatory Markers ◽

Diabetic Patients ◽

Control Groups ◽

Type 2 Diabetic Patients ◽

Human Enzyme ◽

Significant Difference ◽

And Control ◽

Type 2 Diabetic

Background: This study aims to investigate the role of ADAMTS7 and ADAMTS12 on atherosclerosis and inflammation in prediabetic and diabetic patients. Patients & methods: Serum ADAMTS7 and ADAMTS12 levels were compared with the atherosclerotic and inflammatory markers in diabetic (n = 65, female 30.9%, mean age = 53 years), prediabetic (n = 55, female 36.6%, mean age = 49 years) and control groups (n = 55, females 32.5%, mean age = 49 years). Serum ADAMTS levels were determined by a human enzyme-liked immunoassay. Results: In terms of ADAMTS7, there was no significant difference between diabetic, prediabetic and control groups (50.93, 44.34, 59.07, respectively; p > 0.05). ADAMTS12 is lower in diabetics (p < 0.05), whereas it is similar in prediabetics and controls (14.53, 20.76, 25.05, respectively; p > 0.05). ADAMTS7 and ADAMTS12 levels did not differ in diabetic nephropathy, retinopathy and neuropathy (p > 0.05). Conclusion: While ADAMTS12 was significantly lower in diabetics and prediabetics, ADAMTS7 and ADAMTS12 were not related to diabetic complications (nephropathy, retinopathy and neuropathy).

Download Full-text

Effects of One Year Treatment of Sibutramine on Insulin Resistance Parameters in Type 2 Diabetic Patients

Journal of Pharmacy & Pharmaceutical Sciences ◽

10.18433/j3388p ◽

2010 ◽

Vol 13 (3) ◽

pp. 378 ◽

Cited By ~ 9

Author(s):

Giuseppe Derosa ◽

Pamela Maffioli ◽

Ilaria Ferrari ◽

Ilaria Palumbo ◽

Sabrina Randazzo ◽

...

Keyword(s):

Insulin Resistance ◽

Body Weight ◽

Density Lipoprotein ◽

Control Group ◽

Diabetic Patients ◽

Type 2 Diabetic Patients ◽

Hs Crp ◽

One Year ◽

Type 2 Diabetic

Purpose. Comparison of the effects of one year treatment with sibutramine compared to placebo on body weight, glycemic control, lipid profile, and insulin resistance parameters in type 2 diabetic patients. Methods. Two hundred and forty-six patients with uncontrolled type 2 diabetes mellitus in therapy with different oral hypoglycemic agents or insulin were enrolled in this study and randomised to take sibutramine 10 mg or placebo for one year. We evaluated at baseline, and after 3, 6, 9, and 12 months these parameters: body weight, body mass index (BMI), glycated hemoglobin (HbA1c), fasting plasma glucose (FPG), post-prandial plasma glucose (PPG), fasting plasma insulin (FPI), homeostasis model assessment insulin resistance index (HOMA-IR), total cholesterol (TC), low density lipoprotein-cholesterol (LDL-C), high density lipoprotein-cholesterol (HDL-C), triglycerides (Tg), retinol binding protein-4 (RBP-4), resistin, visfatin, and high sensitivity-C reactive protein (Hs-CRP). Results. We observed a faster improvement of HbA1c, FPG and PPG with sibutramine compared to the control group; furthermore we recorded a decrease of FPI, TC, LDL-C, body weight, and BMI in the sibutramine group, but not in the control group. A faster decrease of HOMA-IR, resistin, and RBP-4 was recorded with sibutramine compared to the control group. We observed a significant decrease of Hs-CRP in both groups. Conclusions. Sibutramine gave a faster improvement of glycemic control, and of insulin resistance parameters compared to placebo; furthermore sibutramine gave also an improvement of lipid profile, and body weight.

Download Full-text

Status of some Trace Elements in Type-2 Diabetic Patients and its Relationship with Lipid Profile

Journal of Bangladesh Academy of Sciences ◽

10.3329/jbas.v40i1.28327 ◽

2016 ◽

Vol 40 (1) ◽

pp. 79-85 ◽

Cited By ~ 1

Author(s):

Roksana Yeasmin ◽

MA Muttalib ◽

Naznin Sultana ◽

Nizamul Hoque Bhuiyan ◽

Rashedul Alam

Keyword(s):

Lipid Profile ◽

Serum Magnesium ◽

Control Group ◽

P Value ◽

Diabetic Patients ◽

Type 2 Diabetic Patients ◽

Serum Zn ◽

And Control ◽

Type 2 Diabetic

Investigation of the serum level of copper, zinc, magnesium and manganese in type-2 diabetes mellitus and their possible association with lipid profile was carried out. The comparative study included 100 type-2 diabetic patients in Gr-II and 100 non-diabetic as control in (Gr-I). Results indicated that there is a significant lower level (p < .001) of serum Zn, Cu, Mg and Mn in diabetic patients compared with the control group, showing p value < .001. In type-2 DM patients (Gr-II) there were significant correlations between serum Zn and TAG (r = 0.209) and between Zn and HDL-C level (r = .199) showing p value <.05. Non significant relationships were found in between Zn and lipid profile (TAG, Cholesterol, HDL-C and LDL-C) of control (Gr-I) group. Significant correlation was found between serum magnesium and TAG of control (Gr-I) where p < .01 and non significant correlations were found in serum Mg and total cholesterol, HDL-C, LDL-C of both type-2 diabetic (Gr-II) and control (Gr-I). Significant correlations were also found in between serum of Cu and Mn and TAG of control (Gr-I) where p < .05 and non significant correlations were found in other component of lipid profile of both cases (Gr-II) and control (Gr-I).Journal of Bangladesh Academy of Sciences, Vol. 40, No. 1, 79-85, 2016

Download Full-text

Influence of Long-term Statin use in Type 2 Diabetic Patients on Thyroid Nodularity in Iodine-sufficient Area

Experimental and Clinical Endocrinology & Diabetes ◽

10.1055/s-0031-1283123 ◽

2011 ◽

Vol 119 (08) ◽

pp. 497-501 ◽

Cited By ~ 6

Author(s):

M. Chon ◽

J. Suk ◽

K. Oh ◽

K. Kim ◽

Y. Kim ◽

...

Keyword(s):

Thyroid Nodules ◽

Control Group ◽

Diabetic Patients ◽

Type 2 Diabetic Patients ◽

Statin Group ◽

And Control ◽

Type 2 Diabetic ◽

Statin Use

AbstractStatins have marked beneficial effects on lipid profile, but also have pleiotropic actions. A previous study in an iodine-deficient area suggested that statin use is associated with reduced thyroid volume and nodularity. We performed this study to investigate how long-term statin use in type 2 diabetic patients affects thyroid nodularity in iodine-sufficient area.We recruited euthyroid type 2 diabetic patients, receiving statin therapy continuously for at least 5 years (statin group) and, age and sex matched statin-naive type 2 diabetic patients (control group). Subjects with past history of cancer, thyroid disease or treatment with lithium or amiodarone; family history of thyroid cancer; palpable goiter or thyroid nodule, and/or positive thyroperoxidase antibody were excluded. The prevalence, number, and volume of thyroid nodules, size of thyroid were evaluated in all subjects by high resolution ultrasound.Prevalence of non-palpable thyroid nodules of statin group (n=70) and control group (n=98) were 51 and 53% , respectively. There was no difference of prevalence, number, and volume of non-palpable thyroid nodules and size of thyroid between statin and control group. But, the patients aged between 60 and 65 years from statin group showed lower prevalence of non-palpable thyroid nodules than the patients with same age interval from control group (4 out of 12 patients, 33% , statin group; 19 out of 27 patients, 70% , control group; P=0.04).Long-term statin use in elderly type 2 diabetic patients was associated with lesser prevalence of thyroid nodules in an iodine-sufficient area. Our data might support a possible antiproliferative effect of statins on thyroid in old type 2 diabetic patients. But, the effect was not as strong as that in an iodine-deficient area and further studies with enough numbers of subjects and revised design will be needed.

Download Full-text

Association between decreased thyroid stimulating hormone and hyperuricemia in type 2 diabetic patients with early-stage diabetic kidney disease

BMC Endocrine Disorders ◽

10.1186/s12902-020-00672-8 ◽

2021 ◽

Vol 21 (1) ◽

Author(s):

Xiaomeng Feng ◽

Jing Huang ◽

Yan Peng ◽

Yuan Xu

Keyword(s):

Uric Acid ◽

Diabetic Kidney Disease ◽

Early Stage ◽

Thyroid Stimulating Hormone ◽

Control Group ◽

Diabetic Patients ◽

Type 2 Diabetic Patients ◽

And Control ◽

Type 2 Diabetic

Abstract Background Serum uric acid (SUA) is associated with the development of diabetic kidney disease (DKD). Thyroid hormones can regulate metabolism and insulin resistance. The relationship between SUA and thyroid function in patients with DKD is still uncertain. In current study, we aimed to investigate the association between thyroid stimulating hormone (TSH) and SUA in type 2 diabetic patients with early-stage DKD. Methods Two hundred fifty-four type 2 diabetic patients with early-stage DKD were enrolled in current study and were further classified as high SUA group (SUA level > 420 μmol/L in males or > 360 μmol/L in females, n = 101) and normal SUA group (SUA level ≤ 420 μmol/L in males or ≤ 360 μmol/L in females, n = 153). Eighty-five control subjects were recruited as control group. The clinical characteristics were obtained via face-to-face surveys and medical records. Results Compared with normal SUA group and control group, high SUA group exhibited the increased SUA level, and the decreased TSH level (P < 0.017 for all), and no significant difference was detected in SUA and TSH between normal SUA group and control group. TSH was negatively associated with SUA (r = − 0.35, P < 0.001) in type 2 diabetic participants with early-stage DKD. Furthermore, the decreased TSH level was independently correlated with higher SUA level (β = − 25.69, P < 0.001), and retained a significant association with hyperuricemia (odds ratio = 1.73, P = 0.002) after adjusting for confounding factors in type 2 diabetic patients with early-stage DKD. Conclusions TSH is negatively correlated with SUA, and decreased TSH is an independent risk factor for hyperuricemia in type 2 diabetic patients with early-stage DKD. These results indicate that thyroid hormones, TSH in particular, might participate in regulating uric acid metabolism in patients with early-stage DKD.

Download Full-text

Association between Decreased Thyroid Stimulating Hormone and Hyperuricemia in Type 2 Diabetic Patients with Early-stage Diabetic Kidney Disease

10.21203/rs.3.rs-36818/v1 ◽

2020 ◽

Author(s):

Xiaomeng Feng ◽

Jing Huang ◽

Yan Peng ◽

Yuan Xu

Keyword(s):

Uric Acid ◽

Diabetic Kidney Disease ◽

Early Stage ◽

Thyroid Stimulating Hormone ◽

Control Group ◽

Diabetic Patients ◽

Type 2 Diabetic Patients ◽

And Control ◽

Type 2 Diabetic

Abstract Background Serum uric acid (SUA) is associated with the development of diabetic kidney disease (DKD). Thyroid hormones can regulate metabolism and insulin resistance. The relationship between SUA and thyroid function is still uncertain. Methods 254 type 2 diabetic patients with early-stage DKD were enrolled in current study and were further classified as high SUA group (SUA > 360 µmol/L, n = 126) and normal SUA group (SUA ≤ 360 µmol/L, n = 128). 85 control subjects were recruited as control group. The clinical characteristics were obtained via face-to-face surveys and medical records. Results Compared with normal SUA group and control group, high SUA group exhibited the increased SUA, free triiodothyronine and free thyroxine levels, and the decreased thyroid stimulating hormone (TSH) level (P < 0.017 for all), and no significant difference was detected in these parameters between normal SUA group and control group. Furthermore, the increased creatinine (β = 2.049, P < 0.001), triglycerides (β = 10.068, P < 0.001), urinary albumin-to-creatinine ratio (β = 0.262, P = 0.001), fasting blood glucose (β = 5.280, P = 0.003) and fasting insulin (β = 1.440, P = 0.034) levels, and the decreased TSH (β = -24.906, P < 0.001) level were independently correlated with higher SUA level in type 2 diabetic patients with early-stage DKD. Notably, decreased TSH retained a significant association (odds ratio = 1.654, P = 0.002) with hyperuricemia in type 2 diabetic patients with early-stage DKD. Conclusions TSH is negatively correlated with SUA, and decreased TSH is an independent risk factor for hyperuricemia in type 2 diabetic patients with early-stage DKD. These results indicate that thyroid hormones, TSH in particular, might participate in regulating uric acid metabolism in patients with early-stage DKD.

Download Full-text